Maternal RSV vaccine cuts infant hospitalizations by 70%, study shows
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Associate Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
A study led by researchers at the University of Pittsburgh and UPMC published in JAMA Network Open, found that vaccination against respiratory syncytial virus (RSV) during pregnancy reduced the risk of hospitalization in young infants by nearly 70%.
This study provides early real-world evidence from U.S. clinical care, showing that administering one dose of the maternal RSV vaccine (RSVpreF vaccine) reduces hospitalization related to RSV in young infants. The results are consistent with findings from RSVpreF vaccine clinical trials. The RSVpreF vaccine was approved by the U.S. Food and Drug Administration in 2023.
"We designed this study to focus on what matters most to families: whether their baby might end up in the hospital," said lead author of the study, Anne-Marie Rick, M.D., Ph.D., assistant professor of pediatrics and clinical and translational science at Pitt School of Medicine and a physician at UPMC Children's Hospital of Pittsburgh and UPMC Magee-Womens Hospital.
"The findings show a significant impact for families and for the health system, and it highlights how effective this intervention can be during the most vulnerable months of life."
RSV is the leading cause of hospitalization among infants in the United States. According to the Centers for Disease Control and Prevention (CDC), about two to three out of every 100 babies younger than 3 months are hospitalized each year due to RSV, with severe cases sometimes requiring oxygen support or mechanical ventilation. Until the RSVpreF vaccine's approval, there was no reliable way to protect healthy newborns from RSV starting at birth.
The study analyzed health records from infants 90 days old or younger who were hospitalized for respiratory illness in western Pennsylvania during the 2023–24 and 2024–25 RSV seasons.
Researchers focused on infants who were tested for RSV and compared outcomes between those whose mothers received the vaccine during pregnancy and those whose mothers did not. Infants who received monoclonal antibody protection—a separate RSV prevention option administered after birth—were excluded.
Among infants younger than 3 months, maternal vaccination was associated with approximately 68% effectiveness against hospitalization for respiratory illness caused by RSV and 69% effectiveness against more severe lung infections also caused by the virus.
The results are part of an ongoing four-year study to evaluate the effectiveness of maternal RSV vaccination across multiple seasons. Researchers will continue to follow patients during the 2025–26 and 2026–27 RSV seasons, expanding the analysis to include infants up to 180 days old and assessing how long protection lasts.
"We're continuing to follow patients to understand how well this protection holds over time and across different groups," said Rick. "These kinds of real-world data are critical for helping families, clinicians, and policymakers make informed decisions about how best to protect infants."
Publication details
Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants, JAMA Network Open (2026). DOI: 10.1001/jamanetworkopen.2026.16773
Journal information: JAMA Network Open
Key medical concepts
Clinical categories
PediatricsChildren's healthObstetrics & gynecologyInfectious diseasesPregnancyCommon illnesses & Prevention Provided by University of Pittsburgh Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Maternal RSV vaccine cuts infant hospitalizations by 70%, study shows (2026, June 5) retrieved 9 June 2026 from https://medicalxpress.com/news/2026-06-maternal-rsv-vaccine-infant-hospitalizations.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.